美国 · SEC FORM 4
ALX ONCOLOGY HOLDINGS INC
ALXO · Nasdaq · CIK 0001810182 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
3 同一窗口内观察到的 Form 4 交易行
3 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-02-02 · GOODMAN COREY S.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -41.1%
- 3M
- -44.1%
- 6M
- -37.8%
- 12M
- —
波动率与流动性
- 波动率
- 91.8%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- -391.4%
- 细分行业
- Biotechnology
市场数据
价格数据截至:2026-10-02 · 价格来源:OpenBB/yfinance · 来自 SEC 申报文件:ROE · 财年截止日:2025-12-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 5,673,137
- 上期报告
- 6,273,652
- 日均成交量
- 1,495,736
- 回补天数
- 3.8
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-02 | GOODMAN COREY S | 买入 (P) | Common Stock | 3,184,713 | USD 1.57 | USD 4,999,999 | SEC 申报 ↗ |
| 2025-09-17 | Lettmann Jason | 买入 (P) | Common Stock | 71,163 | USD 1.08 | USD 76,856 | SEC 申报 ↗ |
| 2025-09-16 | Lettmann Jason | 买入 (P) | Common Stock | 21,070 | USD 1.07 | USD 22,545 | SEC 申报 ↗ |
| 2025-08-18 | Shantharam Harish | 买入 (P) | Common Stock | 75,000 | USD 0.78 | USD 58,500 | SEC 申报 ↗ |
| 2024-12-02 | Hemrajani Rekha | 买入 (P) | Common Stock | 30,000 | USD 1.55 | USD 46,500 | SEC 申报 ↗ |
| 2024-06-13 | GARCIA PETER S | 买入 (P) | Common Stock | 12,000 | USD 8.53 | USD 102,360 | SEC 申报 ↗ |
| 2024-06-13 | GARCIA PETER S | 买入 (P) | Common Stock | 12,000 | USD 8.53 | USD 102,360 | SEC 申报 ↗ |
| 2024-03-14 | Lettmann Jason | 买入 (P) | Common Stock | 4,400 | USD 11.31 | USD 49,764 | SEC 申报 ↗ |
| 2020-12-14 | Graham G. Walmsley | 买入 (P) | Common Stock | 20,000 | USD 76.00 | USD 1,520,000 | SEC 申报 ↗ |
| 2020-07-21 | Carusi Michael A; George Jean; LSV Associates II, LLC; LSV Associates, LLC; Lightstone Ventures (A), L.P.; Lightstone Ventures II (A), L.P.; Lightstone Ventures II, L.P.; Lightstone Ventures, L.P.; Plain Henry A JR | 买入 (P) | Common Stock | 400,000 | USD 19.00 | USD 7,600,000 | SEC 申报 ↗ |
| 2020-07-21 | Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC; Vivo Opportunity Fund, L.P.; Vivo Opportunity, LLC | 买入 (P) | Common Stock | 975,000 | USD 19.00 | USD 18,525,000 | SEC 申报 ↗ |
| 2020-07-21 | Pietzke Steffen | 买入 (P) | Common Stock | 3,000 | USD 19.00 | USD 57,000 | SEC 申报 ↗ |
| 2020-07-21 | Lettmann Jason | 买入 (P) | Common Stock | 400,000 | USD 19.00 | USD 7,600,000 | SEC 申报 ↗ |
| 2020-07-21 | Hemrajani Rekha | 买入 (P) | Common Stock | 3,000 | USD 19.00 | USD 57,000 | SEC 申报 ↗ |
| 2020-07-21 | Graham G. Walmsley | 买入 (P) | Common Stock | 975,000 | USD 19.00 | USD 18,525,000 | SEC 申报 ↗ |
Form 4 申报证据
9 transaction lines in the latest 365-day window; 276 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Wong Shelly | 卖出 (S) | Common Stock | 573 | USD 1.93 | USD 1,106 | SEC 申报 ↗ |
| 2026-08-17 | Lettmann Jason | 卖出 (S) | Common Stock | 2,230 | USD 1.93 | USD 4,304 | SEC 申报 ↗ |
| 2026-07-01 | Wong Shelly | 卖出 (S) | Common Stock | 1,404 | USD 2.04 | USD 2,864 | SEC 申报 ↗ |
展开近期 Form 4 证据 (9 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Wong Shelly | 卖出 (S) | Common Stock | 573 | USD 1.93 | USD 1,106 | SEC 申报 ↗ |
| 2026-08-17 | Lettmann Jason | 卖出 (S) | Common Stock | 2,230 | USD 1.93 | USD 4,304 | SEC 申报 ↗ |
| 2026-07-01 | Wong Shelly | 卖出 (S) | Common Stock | 1,404 | USD 2.04 | USD 2,864 | SEC 申报 ↗ |
| 2026-03-19 | Pinto Shelly | 卖出 (S) | Common Stock | 903 | USD 2.17 | USD 1,960 | SEC 申报 ↗ |
| 2026-03-19 | Lettmann Jason | 卖出 (S) | Common Stock | 12,311 | USD 2.17 | USD 26,715 | SEC 申报 ↗ |
| 2026-02-18 | Pinto Shelly | 卖出 (S) | Common Stock | 565 | USD 2.27 | USD 1,283 | SEC 申报 ↗ |
| 2026-02-17 | Lettmann Jason | 代扣税 (F) | Common Stock | 2,201 | USD 2.27 | USD 4,996 | SEC 申报 ↗ |
| 2026-02-02 | GOODMAN COREY S | 买入 (P) | Common Stock | 3,184,713 | USD 1.57 | USD 4,999,999 | SEC 申报 ↗ |
| 2026-01-06 | Pinto Shelly | 卖出 (S) | Common Stock | 3,925 | USD 1.11 | USD 4,357 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ALXO |
| CIK | 0001810182 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 276 transaction lines from 2020-07-21 to 2026-08-17 22 P purchase lines · 188 S sale lines · 66 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.